P rofound hemodynamic and metabolic changes occur during adult orthotropic liver transplantation (1) . The conventional approach to optimize hemodynamic parameters, which involves generous fluid loading to maintain arterial pressure and renal perfusion during periods of caval compression and clamping, has been questioned. This is because the distribution of blood volume and pooling in the splanchnic circulation is altered in patients who have cirrhosis and portal hypertension (2) , and rapid expansion of blood volume in these patients increases portal hyperemia and blood loss, whereas increases in cardiac output are blunted.
There is growing interest in drugs such as vasopressin that can be used during surgery to limit blood flow selectively to the gut to reduce surgical bleeding (3) . More recently, short-term infusion of vasopressin has been used successfully during liver transplantation with significant reduction of portal venous pressure without any sign of splanchnic hypoperfusion (4) .
Terlipressin (tricyl-lysine-vasopressin) is a synthetic analog of vasopressin. It has a similar pharmacodynamic profile but different pharmacokinetic properties to the parent drug (5) . Although several studies have investigated the effects of terlipressin on systemic, portal, and renal hemodynamics in patients with cirrhosis (6, 7) , the clinical use and safety profile of the intraoperative use of terlipressin in such patients has been entirely unknown until now.
The randomized controlled study described here was conducted primarily to investigate the effect of a continuous infusion of terlipressin on systemic and splanchnic hemodynamics and to assess its effect on renal function in patients undergoing living donor liver transplantation.
MATERIALS AND METHODS
The study was designed to recruit patients with end-stage liver disease who were scheduled for living donor liver transplantation. After approval by the local ethics and research committee, written informed consent was obtained from each participant. Enrollment of patients started in June 2008 and ended in January 2010. We enrolled patients who fulfilled the following criteria: 1) the presence of (Child-Turcotte-Pugh) grade C liver cirrhosis; and 2) significant portal hypertension (portal pressure Ͼ20 mm Hg).
The exclusion criteria were: age Ͻ18 yrs, patients undergoing retransplantation, a history of upper abdominal surgery, portal vein thrombosis (diagnosed using preoperative duplex ultrasound), and primary renal dysfunction.
A standardized anesthetic protocol was used (8) . Exposure of the portal vein was facilitated by division of the peritoneum of the hepatoduodenal ligament. The right and left hepatic arteries were dissected, and the common bile duct was divided at the bifurcation of the right and left hepatic ducts. After ligation of the hepatic artery and surgical exposure of the portal vein, a 22-gauge needle was inserted into the portal vein and connected to a pressure transducer. Only patients with a portal pressure of Ͼ20 mm Hg were allocated randomly to receive either an initial bolus dose of terlipressin (1 mg over 30 mins) followed by a continuous infusion of 2 g⅐kg Ϫ1 ⅐h Ϫ1 for 2 days (TP group: n ϭ 15) or the same volume of 0.9% saline (control group: n ϭ 15). Randomization was performed using closed envelopes (15 that contained the TP and 15 that contained the control allocation). In both groups, the patients received a 250-mL bolus of 5% albumin to maintain the central venous pressure (central venous pressure) between 5 and 7 mm Hg. Blood transfusion was given if the level of hemoglobin was Ͻ7 g/dL. Norepinephrine was administered if the mean arterial pressure was Ͻ70 mm Hg and the systemic vascular resistance was Ͻ600 dyne.sec.cm Ϫ5 . Epinephrine was administered if mean arterial pressure was Ͻ70 mm Hg and the cardiac index was Ͻ2.5 L⅐min⅐m Ϫ2 despite sufficient volume infusion to maintain a target cardiac index of 2.5-3.0 L⅐min⅐m Ϫ2 . Our protocol of postoperative fluid therapy and transfusion of blood and blood products, and the use of diuretics, has been described previously (8) .
Measurement and Calculation of Hemodynamics. Systemic and pulmonary hemodynamics and calculated tissue oxygenation parameters were recorded after ligation of the hepatic artery and before drug administration (baseline), 2 hrs after drug administration, at the end of the anhepatic phase, 30 mins after reperfusion, at the end of the surgery, and on the first 2 days after surgery.
Pressure in the portal vein and gas exchange (radial artery, portal vein, and hepatic vein blood gas analyses, and lactate concentration) were measured at baseline (after ligation of the hepatic artery) and 2 hrs after drug administration. Total splanchnic, gastrointestinal, and hepatic lactate gradients were calculated as described previously (9) . Routine Doppler ultrasound was performed daily during the first week postoperatively to detect any postoperative vascular complications. As part of the examination, peak portal blood flow velocity (portal Vmax) was measured with Doppler spectrograms obtained at the recipient portal vein (Ͻ1 cm proximal to the anastomosis) with angle correction. The mean values of portal Vmax on postoperative days 1 and 2 were calculated and recorded.
Assessment of Renal Function. The renal function of all the enrolled patients was monitored by measuring serum creatinine and serum cystatin C and by calculating creatinine clearance from a complete 24-hr urine collection. The serum concentration of cystatin C was measured by means of latex-amplified nephelometry using the N Latex Cystatin C kit (Dade Behring Diagnostics, Mannheim, Germany) and the BN-II System (Dade Behring Diagnostics) (10) . Serum creatinine and cystatin C were measured after induction of anesthesia and on the first 2 days after surgery. Creatinine clearance was measured on postoperative day 4 and at the time of discharge from the hospital.
Other Variables. The use of intravascular volume replacement therapy, including colloid infusion and transfusions of packed red blood cells and fresh-frozen plasma, was recorded daily during the first 4 days in the intensive care unit. Urine output, the dose of diuretics, and the total amount of ascitic fluid were also recorded. Liver function tests (aspartate aminotransferase, alanine aminotransferase, international normalized ration, and bilirubin) were carried out on postoperative day 4.
Statistical Analysis. Power analysis was performed on the level of cystatin C 24 hrs after surgery for independent samples using Student's t test because it was the main outcome variable in the present study. A previous study showed that a change in the level of cystatin C from 1.7 to 2.2 mg/dL is associated with a change in the glomerular filtration rate from 60 to 40 mL/min with SD 0.4 (11) . On the basis of the assumption that a mean difference of 20 mL/min in the glomerular filtration rate was a clinically significant difference between groups, and for a power of 0.8 and an ␣ error of 0.05, a minimum sample size of 12 patients was calculated for each group. A total of 15 patients was included in each group to compensate for possible dropouts.
Categorical variables were assessed using the chi-square or Fisher's exact test where appropriate. Normally distributed data are presented as the mean (SD). Hemodynamic and laboratory variables with a normal distribution were analyzed using Student's t test and two-way analyses of variance with repeated measures and Dunnett's post hoc test as appropriate. Data that were not normally distributed (by the Kolmogorov-Smirnov test) are presented as the median (range) and were analyzed with the Mann-Whitney U test or the Kruskal-Wallis test as appropriate. Paired variables within each group (ie, values before and after the start of the administration of terlipressin) were compared with either a paired t test in the case of variables with a normal distribution or a Wilcoxon matched-pairs test in the case of variables with a nonnormal distribution.
The software SPSS version 15.0 for Windows (SPSS, Inc, Chicago, IL) was used for statistical analysis.
RESULTS
Of the 43 patients with cirrhosis who had been screened and met the inclusion criteria of the study, 13 patients had to be excluded owing to low portal venous pressure (Ͻ20 mm Hg; n ϭ 10) or portal vein thrombosis that was discovered incidentally during the operation (n ϭ 3). All 30 enrolled patients completed the study. Demographic and perioperative data were comparable between the two groups ( Table 1 ). The relation of the donors to recipients is shown in Table 2 .
Systemic Hemodynamics. The mean arterial blood pressure, central venous pressure, and systemic vascular resistance were significantly higher in the TP group than in the control subjects from 2 hrs after clamping of the hepatic artery. In contrast, heart rate, cardiac index, pulmonary vascular resistance, oxygen delivery, and oxygen consumption were not significantly different between the groups (Table 3) .
Splanchnic Hemodynamics and AcidBase Homeostasis. The initiation of the infusion of terlipressin was accompanied by a significant reduction of portal pressure from 25.3 Ϯ 3.2 mm Hg to 21.1 Ϯ 3.3 mm Hg (p Ͻ .0001), whereas in the control group, the portal pressure remained unchanged throughout the study protocol (Fig. 1) . The mean values of portal Vmax measured on postoperative days 1 and 2 in patients assigned to the control group were 69 Ϯ 12 cm/sec and 61 Ϯ 8 cm/sec, respectively. These values were significantly higher than those of the TP group, which were 58 Ϯ 8 cm/sec and 49 Ϯ 6 cm/sec (p ϭ .016 and .002, respectively).
The hepatosplanchnic acid-base variables are summarized in Table 4 . There were no significant overall differences between the two groups in any variable of acid-base homeostasis. In the control group, portal and hepatic venous pH as well as the base excess decreased significantly compared with baseline, whereas terlipressin infusion attenuated the hepatosplanchnic metabolic acidosis in the TP group markedly. Gastrointestinal, hepatic, and total splanchnic lactate gradients were comparable between the groups. Fluids, Urine Output, and Requirement for Norepinephrine. The mean volume of colloids administered intraoperatively in the control group was 4875 Ϯ 1026 mL, which was significantly higher than that in the TP group (3500 Ϯ 1224 mL, p ϭ .008). The amount of intraoperative blood loss was comparable among both groups (2350 Ϯ 895 mL and 2800 Ϯ 1000 mL in TP and control groups, respectively). Postoperatively, the mean volume of colloids infused was 1973 Ϯ 716 mL and 1050 Ϯ 872 mL in the control group and the terlipressin group, respectively (p ϭ .03). The use of packed red blood cells and fresh-frozen plasma did not differ between the two groups. The requirement for norepinephrine was significantly higher in the control group, nine patients (60%), than in the TP group, one patient (6.7%) (p ϭ .002). The mean volume of ascitic fluid collected during the first 4 days after the operation was 2500 Ϯ 1080 mL in the TP group, but it was significantly greater, 3800 Ϯ 1100 mL, in the control group (p ϭ .04). Urine output was significantly higher in the TP group than in the control group, whereas the use of diuretics was significantly greater in the control group (Table 5) .
Laboratory Variables. Serum creatinine and cystatin C were significantly higher in the control group than in the TP group on postoperative day 2 (Figs. 2  and 3 ). Creatinine clearance was significantly lower in the control group than in the TP group on postoperative day 4 (control: 51 Ϯ 28.9, TP: 77.5 Ϯ 29.6 mL⅐min Ϫ1 ; p ϭ .024). At discharge from the hospital, there was no significant difference with respect to creatinine clearance between the groups (control: 77.8 Ϯ 13 mL⅐min Ϫ1 , TP: 79.6 Ϯ 15 mL⅐min Ϫ1 ; p ϭ .7). One patient in the control group developed acute renal failure and required renal replacement therapy 10 days after the operation.
The variables that represented postoperative liver function were similar between the two groups, except for bilirubin, which was significantly higher in the control group (8.4 Ϯ 3.4 mg/dL) than in the TP group (4.4 Ϯ 2.4 mg/dL; p ϭ .009) on postoperative day 4 ( Table 6 ).
DISCUSSION
The main finding of the study described herein was that perioperative infusion of terlipressin during liver transplantation ameliorated the immediate pHpv, portal venous pH; TP, terlipressin group; pHhv, hepatic vein pH; BEpv, portal vein base excess; BEhv, hepatic vein base excess; Lactate art, arterial lactate; Lactate pv, portal vein lactate; Lactate hv, hepatic vein lactate.
a Significant relative to baseline (p Ͻ .05).
postoperative decline of renal function effectively without any sign of splanchnic hypoperfusion. Previous studies have demonstrated that intravenous injection of terlipressin not only improves renal function in patients with hepatorenal syndrome, but also affects systemic and splanchnic hemodynamics in patients with cirrhosis (7, 12) . However, no previous study has investigated the effects of intraoperative administration of terlipressin on systemic and splanchnic hemodynamics or renal function in patients undergoing liver transplantation.
We found that terlipressin increased the mean arterial pressure and systemic vascular resistance without causing any significant reduction in cardiac output, heart rate, or oxygen consumption. Furthermore, the requirement for norepinephrine was significantly lower in the patients treated with terlipressin than in the control group. Patients with cirrhosis and portal hypertension exhibit a hyperdynamic circulation with increased heart rate and cardiac output and decreased mean arterial pressure and systemic vascular resistance (13) . Terlipressin (tricyllysine-vasopressin) is a synthetic analog of arginine vasopressin. It is metabolized rapidly by endopeptidases to form the vasoactive lysine vasopressin, which is characterized by greater selectivity for the V1 vasopressin receptor than arginine vasopressin (14) . The results of the present study support the findings of Narahara et al (7), who also recently reported the effect of terlipressin injections on systemic hemodynamics in patients with cirrhosis. However, we did not observe any decrease in cardiac output during the infusion of terlipressin, as reported by that group.
In our study, the control group required a larger volume of colloid fluid therapy than the TP group to maintain intravascular volume. In patients with portal hypertension, the blood is distributed abnormally with respect to volume, because blood moves into the splanchnic circulation as it expands as a result of portal hypertension (15) . From this point of view, terlipressin might have a beneficial effect on the central blood volume by increasing the effective blood volume through arteriolar vasoconstriction in the splanchnic area and by redistributing blood to the systemic circulation.
The incidence of postoperative renal impairment in orthotropic liver transplantation is high, up to 70%, and it is still associated with considerable morbidity and mortality (16) . In the current study, the use of intravenous terlipressin, which was started intraoperatively and maintained for the first 2 days postoperatively, resulted in a marked increase in urine output and a substantial decrease in serum cystatin C and creatinine. The TP group also displayed a significantly higher creatinine clearance than the control group. Terlipressin enhances renal perfusion through increasing both mean arterial pressure and effective arterial blood volume (7) . Another mechanism of increased diuresis might be mediated by stimulation of V1a receptors (17) .
Nonetheless, administration of terlipressin has been associated with several adverse effects in both preclinical and clinical studies. One of these adverse effects is impairment of intestinal perfusion, which may be induced by terlipressin in patients with esophageal variceal hemorrhage (18) and portal hypertension (19) . In our study, terlipressin decreased portal venous pressure in the native liver significantly without any signs of splanchnic hypoperfusion such as increased portal-arterial gradients of PCO 2 and lactate. In line with our results, Wagener et al (4) reported recently a decreased portal venous pressure in the native diseased liver in patients who were treated with a low-dose infusion of vasopressin during liver transplantation without any signs of splanchnic hypoperfusion.
At the end of the study protocol, total bilirubin and total amount of ascitic fluid were significantly higher in the control group than in the patients treated with terlipressin. Although speculative, this might be the result of a reduction in the portal venous pressure when terlipressin is administered. Consistent with this view, considerable increases in the maximum flow velocity in the portal vein have been shown to be highly correlated with increased total bilirubin levels in transplant recipients on postoperative day 2 (20) . However, the effect of decreased flow in the portal vein in the early phase after liver transplantation requires further study. The present study had several limitations. We did not study the influence of terlipressin infusion on the integrity of renal tubular function by using newly described sensitive markers such as urinary neutrophil gelatinase-associated lipocalin and glutathione transferase-␣. Another limitation of the present study is that only surrogate markers were used to identify the volume status of each patient. Cardiac filling pressures (pulmonary capillary wedge pressure and central venous pressure) do not definitively confirm or exclude hypovolemia.
This research demonstrates the renalprotective effects of terlipressin in the immediate postoperative period for patients with normal kidney function who undergo liver transplantation. However, we cannot judge with confidence whether our findings can be extrapolated to patients with moderate to severe renal impairment.
CONCLUSION
Terlipressin ameliorated the deterioration of renal function in the immediate postoperative period in patients with severe portal hypertension who underwent liver transplantation. Terlipressin decreased portal venous pressure without decreasing hepatosplanchnic perfusion. Further studies are warranted to address the safety aspects of the reduction of portal venous flow in the early phase after liver transplantation.
